Developer of clinical decision support software intended to provide actionable genomic insights. The company's tools enable scientists to quickly and accurately process and analyze whole genomes, exomes and gene panels, incorporate proven AI algorithms and have applications in both hereditary disease and oncology, providing clinical labs, hospital systems, and country-sequencing programs with faster and more accurate diagnoses and reduced turnaround time.
Generating Revenue
Privately Held (backing)
Venture Capital-Backed
The company raised an undisclosed amount of Series C venture funding in a deal led by Mighty Capital on February 1, 2018. Previously, the company raised $23 million of Series B venture funding from UPMC, Roche Venture Fund and LDV Partners on June 8, 2016, putting the company's pre-money valuation at $43.27 million.
Add a review